RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
The purpose of this study is to validate whether clinically low-risk, and RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further improve clinical outcomes.
Breast Cancer|Radiation
RADIATION: regional nodal irradiation|RADIATION: WBI|RADIATION: chestwall XRT
Invasive disease-free survival (IDFS), defined as the time between randomization and either local recur, distant metastases or death occurred, 5 years
Any first recurrence (AFR), defined as any recurrence of ipsilateral chest, breast, regional lymph node recurrence, or distant metastases by Imaging or pathology, 5 years|Local-regional recurrence free survival (LRFS), defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred, 5 years|Distant metastasis free survival (DMFS), defined as time between randomization and the time of distant metastases, or death occurred, 5 years|Recurrence free survival (RFS), defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred, 5 years|Overall Survival (OS), defined as time between randomization and the time of death occurred, 5 years|Disease free survival (DFS), defined as time between randomization and the time of disease recur or death occur, 5 years|Beast cancer specific mortality (BCSM), defined as time between randomization and the time of death occur specific due to breast cancer, 5 years|Patient life quality measurement, At the screening period and after the end of radiotherapy, each group of patients was enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Cancer-30 (C30), 5 years|Patient life quality measurement, At the screening period and after the end of radiotherapy, each group of patients was enrolled in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Breast-23 (BR23), 5 years
The purpose of this study is to validate whether clinically low-risk, and RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further improve clinical outcomes.